Synairgen plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYGGF research report →
Price Chart
About the company
Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD).
- CEO
- Joseph Tregonning Colliver
- IPO
- 2020
- Employees
- 34
- HQ
- Southampton, LO, GB
Get TickerSpark's AI analysis on SYGGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $110.27K
- P/E
- -0.23
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.15
- EV/EBITDA
- -0.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.06%
- ROIC
- -70.80%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-41,286+50.8%
- Op Income
- $-8,324,000
- Net Income
- $-6,811,000+19.0%
- EPS
- $-0.03+19.1%
- OCF Growth
- +5.0%
- FCF Growth
- +4.0%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 6.80
- RSI (14)
- 92
- Avg Volume
- 9.22K
No earnings-call transcripts are available for SYGGF yet.
- Free Float
- 15.4%
- Shares Outstanding
- 1.10B
- Float Shares
- 169.69M
Our SYGGF coverage
Recent articles, reports, and earnings notes.
No research on SYGGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYGGF report →Synairgen shares stay tradeable post-delisting, as top investor waives restrictions
proactiveinvestors.co.uk · Apr 3
Synairgen becomes the latest company to eye the AIM exit door
proactiveinvestors.co.uk · Mar 11
Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI
proactiveinvestors.co.uk · Dec 21
Synairgen backer ready to pump £18-£19 million into phase II trial
proactiveinvestors.co.uk · Dec 20
Synairgen making substantial progress towards phase II trial
proactiveinvestors.co.uk · Sep 26
Synairgen appoints inhaled drug development expert as chairman
proactiveinvestors.co.uk · Sep 18
Synairgen making plans for phase II trial
proactiveinvestors.co.uk · Jun 27
Synairgen appoints new CFO as incumbent bows out after nearly 20 years
proactiveinvestors.com · Oct 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.